|
1
|
Henley D, Isbill M, Fernando R, Foster JS
and Wimalasena J: Paclitaxel induced apoptosis in breast cancer
cells requires cell cycle transit but not Cdc2 activity. Cancer
Chemother Pharmacol. 59:235–249. 2007. View Article : Google Scholar
|
|
2
|
Tan M and Yu D: Molecular mechanisms of
ERBB2-mediated breast cancer chemoresistance. Adv Exp Med Biol.
608:119–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Frankel A, Buckman R and Kerbel RS:
Abrogation of taxol-induced G2-M arrest and apoptosis in human
ovarian cancer cells grown as multicellular tumor spheroids. Cancer
Res. 57:2388–2293. 1997.PubMed/NCBI
|
|
5
|
Yin S, Bhattacharya R and Cabral F: Human
mutations that confer paclitaxel resistance. Mol Cancer Ther.
9:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaffaroni N, Pennati M, Colella G, Perego
P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG:
Expression of the anti-apoptotic gene survivin correlates with
taxol resistance in human ovarian cancer. Cell Mol Life Sci.
59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J,
Belmont LD, Kaminker JS, O’Rourke KM, Pujara K, Kohli PB, Johnson
AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S,
Ludlam MJ, Leong KG, Dueber EC, Maecker H, Huang DC and Dixit VM:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferlini C, Cicchillitti L, Raspaglio G,
Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico
M, Fattorusso C, Campiani G and Scambia G: Paclitaxel directly
binds to Bcl-2 and functionally mimics activity of Nur77. Cancer
Res. 69:6906–6914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu D, Liu B, Jing T, Sun D, Price JE,
Singletary SE, Ibrahim N, Hortobagyi GN and Hung MC: Overexpression
of both p185c-ERBB2 and p170mdr-1 renders breast cancer cells
highly resistant to taxol. Oncogene. 16:2087–2094. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding Y, Liu Z, Desai S, Zhao Y, Liu H,
Pannell LK, Yi H, Wright ER, Owen LB, Dean-Colomb W, Fodstad O, Lu
J, LeDoux SP, Wilson GL and Tan M: Receptor tyrosine kinase ERBB2
translocates into mitochondria and regulates cellular metabolism.
Nat Commun. 3:12712012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann NY Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen T, Pengetnze Y and Taylor CC: Src
inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells
by caspase-9-independent activation of caspase-3. Mol Cancer Ther.
4:217–224. 2005.PubMed/NCBI
|
|
13
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aledo JC, Gómez-Fabre PM, Olalla L and
Marquez J: Identification of two human glutaminase loci and
tissue-specific expression of the two related genes. Mamm Genome.
11:1107–1110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gómez-Fabre PM, Aledo JC, Del
Castillo-Olivares A, Alonso FJ, Nunez De Castro I, Campos JA and
Marquez J: Molecular cloning, sequencing and expression studies of
the human breast cancer cell glutaminase. Biochem J. 345:365–375.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dang CV: Glutaminolysis: supplying carbon
or nitrogen or both for cancer cells? Cell Cycle. 9:3884–3886.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wise DR and Thompson CB: Glutamine
addiction: a new therapeutic target in cancer. Trends Biochem Sci.
35:427–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP and
Tan M: Warburg effect in chemosensitivity: targeting lactate
dehydrogenase-A re-sensitizes taxol-resistant cancer cells to
taxol. Mol Cancer. 9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng M, Chen S, Lao T, Liang D and Sang N:
Nitrogen anabolism underlies the importance of glutaminolysis in
proliferating cells. Cell Cycle. 9:3921–3932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Durán RV, Oppliger W, Robitaille AM,
Heiserich L, Skendaj R, Gottlieb E, et al: Glutaminolysis activates
Rag-mTORC1 signaling. Mol Cell. 47:349–358. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de la Rosa V, Campos-Sandoval JA,
Martin-Rufian M, Cardona C, Mates JM, Segura JA, Alonso FJ and
Marquez J: A novel glutaminase isoform in mammalian tissues.
Neurochem Int. 55:76–84. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seltzer MJ, Bennett BD, Joshi AD, Gao P,
Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS,
Rabinowitz JD, et al: Inhibition of glutaminase preferentially
slows growth of glioma cells with mutant IDH1. Cancer Res.
70:8981–8987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao P, Tchernyshyov I, Chang TC, Lee YS,
Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and
Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial
glutaminase expression and glutamine metabolism. Nature.
458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qie S, Chu C, Li W, Wang C and Sang N:
ERBB2 activation upregulates glutaminase 1 expression which
promotes breast cancer cell proliferation. J Cell Biochem.
115:498–509. 2014. View Article : Google Scholar
|
